ECMO (体外式膜型人工肺) システム市場 - 成長、動向、予測
Extra Corporeal Membrane Oxygenation (ECMO) System Market - Growth, Trends, and Forecast (2020 - 2025)
|ECMO (体外式膜型人工肺) システム市場 - 成長、動向、予測|
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
ECMO (体外式膜型人工肺) システム、通称エクモ市場の成長には、心血管疾患および呼吸器疾患の増加、肺移植における採用の増加、ECMOセンターの増加、認知度を高めるための会議やトレーニングプログラムの増加、技術の進歩などが寄与していると考えられます。さらに、インドや中国のような人口の多い国では、高齢者人口や病気に苦しむ人の数が増加しており、ECMOシステムに大きな成長の機会を提供するでしょう。
当レポートでは、世界のECMO (体外式膜型人工肺) 市場を調査し、市場の概要、応用領域・モダリティ・地域別の市場動向、市場規模の推移と予測、市場シェア、市場促進・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。
The growth of the extracorporeal membrane oxygenation (ECMO) system market can be contributed to the growing cardiovascular and respiratory diseases, rising adoption of ECMO as a bridge to lung transplantation, growing number of ECMO centers, conferences & training programs to increase awareness, and technological advancements. In addition, the rising geriatric population and the number of people suffering from diseases in populous countries such as India & China are factors that are expected to offer significant growth opportunities for ECMO systems.
However, complications associated with extracorporeal membrane oxygenation machine such as bleeding, infections, and technical failures; along with high cost and lack of skilled professionals is a challenge to the market.
Respiratory Applications is expected to Dominate the Market
Asthma is one of the major noncommunicable diseases. It is a chronic disease of the air passages of the lungs which inflames and narrows them. According to a World Health Organization 2017 report, there are approximately 235 million people suffering from asthma globally. As per this report, there were 383,000 deaths due to asthma in 2015. Moreover, the prevalence of asthma seems to be increasing at a rapid pace.
As per the Center for Disease Control and Prevention (CDC) 2016 report, the prevalence of asthma among adults aged 20 and over increased from 7.1% in 2009-2010 to 9.2% in 2013-2014. Therefore ECMO is useful as to provide adequate gas exchange and prevent lung injury induced by mechanical ventilation. This is very helpful for asthama patients.
As a result, the use of ECMO in cases of near-fatal asthma (NFA) has increased over the years, as per a report by Hye Ju Yeo et al., published in Critical care Journal 2017. Hence all these factors are expected to help the market growth.
North America is Expected to Dominate the Market
As per the American heart association, coronary heart disease is the leading cause of deaths (45.1%) attributable to the cardiovascular disease in the United States, followed by stroke (16.5 %) and heart failure (8.5 %). Moreover, about 5.7 million adults in the United States die of heart failure every year, of which the percentage of in-hospital failures holds a huge potential to be reduced by the usage of ECMO. COPD is the third-leading cause of death in the United States, with its prevalence increasing in direct correlation with changing demography. Although, non-invasive mechanical ventilation (NIV) is the primary prognosis, a shift has been observed, in recent years, toward ECMO (which is considered to be a more efficient alternative).
According to a recent article published in 2018, the use of extracorporeal membrane oxygenation (ECMO) has been exponentially increasing over the last decade and is now considered as a mainstream lifesaving treatment modality in critical care medicine.
Hence, the survival rates for adults with severe acute respiratory failure treated with ECMO have also improved dramatically over the past 30 years. These factors are expected to help the market grow in the region.
Majority of the extra corporeal membrane oxygenation system are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.